Please assess the completion status of the following clinical trial:

Trial Title: Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 2 to 11 years on the day of inclusion.~* Participant in good health, based on medical history, physical examination and laboratory parameters.~* Provision of Assent Form signed by the participants (for participants \>=8 years old) and Informed Consent Form signed by the parents or another legally acceptable representative (and by an independent witness for illiterate parent\[s\]).~* Participant and parents/legally acceptable representative able to attend all scheduled visits and to comply with all trial procedures.~* For a female participant of child-bearing potential (girls post-menarche), avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to first vaccination, until at least 4 weeks after the last vaccination.~* Documented receipt of yellow fever vaccine since at least one month before the first vaccination.~Exclusion Criteria :~* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.~* For a female participant of child-bearing potential (girls post-menarche), known pregnancy.~* For a female participant of child-bearing potential (girls post-menarche), known pregnancy or positive pregnancy test in blood sample taken at Screening.~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the trial.~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.~* Known systemic hypersensitivity to any of the vaccines components or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances.~* Systemic hypersensitivity to YF vaccine or history of a life-threatening reaction to YF vaccine.~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.~* Current or past alcohol abuse or drug addiction that may interfere with the participant's ability to comply with trial procedures.~* Receipt of any blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response.~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.~* Planned receipt of any vaccine in the 4 weeks following the first trial vaccination.~* Human Immunodeficiency Virus, hepatitis B antigen, or hepatitis C seropositivity in blood sample taken at Screening.~* Clinically significant laboratory abnormalities (as determined by the Investigator) in blood sample taken at Screening.~* Known previous vaccination with pneumococcal polysaccharide vaccine.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- CYD Dengue vaccine group (Type: EXPERIMENTAL): Participants received three injections of the CYD Dengue vaccine at 0, 6, and 12 months. Participants were followed for 6 months after the last vaccination (up to 18 months).
- Control group (Type: PLACEBO_COMPARATOR): Participants received two injections of placebo, and one injection of pneumococcal polysaccharide vaccine (Pneumo23®) at 0, 6, and 12 months, respectively. Participants were followed for 6 months after the last vaccination (up to 18 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).